Compare VF Corp (VFC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VF Corp vs Viatris Inc — how do they compare? VF Corp trades at $16.88 (market cap $6.62B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 3× VF Corp's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| VFC | VTRS | |
|---|---|---|
Market Cap | $6.62B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $21.55 | $17.39 |
52-Week Low | $11.66 | $8.74 |
Enterprise Value | $10.77B | $32.00B |
Dividend Yield | 2.13% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VFC trades at $16.91, down 0.41% with a bearish technical signal. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025, though recent quarters beat EPS estimates. Net income turned negative in 2025 at -$190M, but 2026 projections show recovery to $255M profit. Valuation metrics appear reasonable with P/E of 26.38 and P/S of 0.7, while analyst consensus targets $19.33 with 43% buy ratings.
VFC faces turnaround challenges with weak Vans performance and consumer headwinds, but improving margins and debt reduction provide catalysts. The stock offers potential upside to analyst targets if brand recovery continues, though execution risks remain elevated given recent volatility and competitive pressures in apparel retail.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
